# Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

> **NCT01614795** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 46 (actual)

## Conditions studied

- Childhood Alveolar Soft Part Sarcoma
- Childhood Angiosarcoma
- Childhood Epithelioid Sarcoma
- Childhood Fibrosarcoma
- Childhood Gliosarcoma
- Childhood Leiomyosarcoma
- Childhood Liposarcoma
- Childhood Malignant Peripheral Nerve Sheath Tumor
- Childhood Synovial Sarcoma
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Osteosarcoma
- Rhabdomyosarcoma

## Interventions

- **BIOLOGICAL:** Cixutumumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01614795
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-18
- **Primary completion:** 2014-04-01
- **Final completion:** 2014-04-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2018-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01614795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01614795, "Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01614795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*